Finally, the potent effect of IL-15 stimulation on NK cell has the potential to increase ADCC activity in future combinations with the rituximab, daratumumab and other monoclonal antibody. Neoleukins lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding. Following the conclusion of the prepared remarks, we will conduct a question-and-answer session, and instructions will follow at that time. Change value during other periods is calculated as the difference between the last trade and the most recent settle. Narula, who has been with Pfizer for 16 years, is currently CFO of Upjohn. Learn how the CFO's partnership with supply chain managers can address current and future pain points. Please. And that requires a lot of follow-up. Our preclinical data suggests that NL-201 could benefit patients broadly across many indications and in combination with a wide variety of standard of care agents. 2021 was a busy year for Neoleukin. Prior to becoming CFO in February 2018, she served in a series of leadership roles throughout her 20 years with SunTrust, including head of commercial and business banking and CEO of the Atlanta division. Will Restaurant Week Be the Ticket? Thanks. I would now like to turn the call over to Julie Rathbun, Communications for Neoleukin Therapeutics. I truly value the time Ive spent with Neoleukin and have enjoyed being able to contribute to a successful transition following the merger with Aquinox, said Mr. Alam. Before we start, Id like to remind you that todays call will include forward-looking statements based on current expectations. I think you know the purpose of the expansion as we get to RP2D is to select validated tumor types or you know IL-2 has activity, so we get we can get a better sense as what efficacy looks like in those disease phase. Priti, you want to take that? And you know press release says that trial will enroll up to I think it was 123 patients or something like that. In addition to Neo-5171, our current discovery stage pipeline includes a T-reg agonist program targeting autoimmune and inflammatory conditions and a next-generation IL-2, IL-15 agonists for oncology indications. So youre asking specifically about renal cell and melanoma within our dose escalation and that sort of mix of patients. This trial will evaluate two different schedules, an ascending dose levels of NL-201 in order to assess safety, pharmacokinetics, pharmacodynamics and antitumor activity. Sources: FactSet, Dow Jones, ETF Movers: Includes ETFs & ETNs with volume of at least 50,000. This is Mary Kate on for Greg, thanks for taking our question. I look forward to working with Rohan on the Board. We use cookies to optimize your experience on our website and for analytics and advertising purposes. Thanks for taking our question. Sun most recently served as chief financial officer and chief strategy officer at biopharmaceutical company SutroVax. Sources: FactSet, Dow Jones, Bonds: Bond quotes are updated in real-time. And so were having a good enrollment and investigator engagement. Before joining Lowes, Mason was vice president, SEC reporting at Bank of America. Operator, we can now open the call up for questions. Thanks, Jonathan and good afternoon, everyone. But we are thinking that potentially, there may be a difference with this molecule, because of the favorable benefit to immune activation at low doses. Were excited for patients and also for the concept of trying to improve upon a proven mechanism of action in IL-2. Industry Dive, Inc. (c) 2022, All rights reserved, 1255 23rd Street, NW, Suite 550, Washington, DC 20037, Meta, LendingClub, Verisk, Lazard, Berkeley Lights, Avangrid, Timbers Company, Icertis, TaylorMade Golf Company, Invesco, Neoleukin Therapeutics, Meredith, Viatris, CAN, Morgan Stanley, Thomson Reuters, Comerica, Driven Brands. Looking forward, we expect a number of upcoming milestones in 2022. Sources: CoinDesk (Bitcoin), Kraken (all other cryptocurrencies), Calendars and Economy: 'Actual' numbers are added to the table after economic reports are released. Sign up to receive CFOs The Balance in your inbox. So I think you know it is we are trying to get a dose and schedule as quickly as possible and as a result, its all relapse and refractory tumor types in this trial. All forward-looking statements included in this presentation are made as of today, and involve assumptions, risks and uncertainties and actual results could differ materially from those anticipated in the forward-looking statements. TaylorMade Golf Companyappointed Rick Paschalas finance chief. Data are provided 'as is' for informational purposes only and are not intended for trading purposes. Priti, anything that youd add to that? At this time, all participants are in listen-only mode. We look forward to sharing our progress with you in the months ahead. And the initial data that we plan to present in the second half of 2022, which is what weve guided to, well focus on safety and tolerability, mostly and in addition, well look at PK/PD from that dose escalation data. Rohan will be replacing Rusty Williams, who will be stepping off the Board after three years.
You may now disconnect. And similar to that, how should we also think about the potential patient follow-up that youll have, especially given that immuno-oncology approaches? We have been extremely fortunate to have Kams guidance these past months after the merger of the two companies. And weve seen that in our preclinical data. Before joining the drug maker, he held financial and operational leadership roles at American Express and Xerox. Sure.
I think you know at the end of 2022, there will be some preliminary efficacy for monotherapy that well take a look at.
We designed and NL-201 to be a potent activator of IL-2 and IL-15 responsive cells, without preferentially binding to cells expressing CD25. For more information, please visit the Neoleukin website:www.neoleukin.com. Anderson resigned from the company to pursue other opportunities. Good afternoon. So maybe not having to start at the very beginning of dose escalation, theres a lot of interests among investigators to start this combination in various tumor types. Ask an AI, I Got a Crash Course in Rodent Control atD.C.s RatAcademy. Neoleukin undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise. So just as a reminder, the first patient was dosed in May of last year. Well provide future updates regarding the status of Neo-5171 and potential development plans.
Sure. Neoleukin undertakes no obligation to update or revise any forward-looking statements. Im also kind of wondering, though, to what extent just given based on the inclusion criteria of your dose escalation, will you might you also have you know empirical data specifically within those patients heading into expansion cohorts? He became CFO in September 2019 to replace outgoing finance chief Muneera Carr. Wirth, who has been with the bank for 15 years, will stay on as a senior adviser through the end of the year.
By continuing to use our site, you agree to our cookie policy. Herzog joined Comerica in 1984 and was most recently executive vice president and treasurer.
Your line is open. Sure. Source: FactSet, Indexes: Index quotes may be real-time or delayed as per exchange requirements; refer to time stamps for information on any delays. The increase was also due to facility-related costs associated with the build out of Neoleukins new laboratory and headquarters in Seattle, Washington.
We have good investigator engagements and are enrolling patients quickly. Please refer to the companys filings with the SEC which are available from the SEC or in the Neoleukin website for information concerning the risk factors that could affect the company. And we have assembled the talented team of more than 90 scientists, clinical developers and biotech professionals to advance our science and develop novel therapies to help patients with serious medical illnesses. Now obviously the selection of RP2D will be you know multifactorial base off of safety. Thanks, everybody for joining our call today. Cryptocurrencies: Cryptocurrency quotes are updated in real-time. Change value during the period between open outcry settle and the commencement of the next day's trading is calculated as the difference between the last trade and the prior day's settle. Eastwood has worked at Thomson Reuters for over 20 years, most recently as senior vice president and head of corporate finance since 2016.Eastwood was formerly chief operating officer of Thomson Reuters Latin America, CFO of the intellectual property and science business, and has also held several senior roles within the finance organization. The science underlying our technology has been published in the prestigious journals, Nature and Science. Thank you. Okay, great. First, we expect to report interim Phase 1 dose escalation data on NL-201 in the second half of the year. In this executive brief based on CFO's June 2022 webinar, you'll learn about the actionable insights CFOs can use to overcome workforce planning challenges amid economic volatility. I let Priti comment on that. Good afternoon, everyone and thanks for taking my questions. We appreciate the dedicated efforts of our talented team at Neoleukin and remain focused on our overriding goal to advance our de novo protein technology platform to benefit patients with serious diseases, including cancer, inflammation and autoimmune diseases. This business guide shares how CFOs from mCloud Technologies, Pact and Quatris Healthco are raising their finance teams profiles and shaping future business decisions. Priti previously served as Vice President, Head of Hematology Clinical Development at AstraZeneca and brings extensive experience in clinical development strategy and trial execution of investigational therapeutics with a specific expertise in oncology and hematologic malignancies. And as weve mentioned previously, due to the pandemic, particularly in 2021, there was some delays at some of the sites in getting it opened. Experimental results indicate that NL-201 causes expansion of cytotoxic memory CD8 T cells and a decrease in T-regulatory CD4 cells in the murine bone marrow. You know we expect dose escalation to start at a dose level, and these are learnings from what weve learned in monotherapy. And how is the current systemic trial informing whether thats an approach thats worth pursuing? By creating completely new molecules, we can optimize multiple parameters, including potency, affinity, stability, size and exactly which parts of the target receptors are engaged. This will be an important year for Neoleukin, as we learn about how our lead molecule performs in patients and continue to focus on extending the potential of our technology.
We ended 2021 with cash and cash equivalents of $142.5 million, compared to $192.6 million at the end of 2020. Lipper shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Meredithnamed Jason Frierottas the publishing companys new chief financial officer, effective March 9. Copyright FactSet Research Systems Inc. All rights reserved. Our next question comes from Joe Catanzaro with Piper Sandler. Cortenbach shares how he begins his day with meditation, the Robert Frost quote that inspires him, and his favorite leadership lesson. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. As a reminder, Neoleukin was founded at the end of 2018, went public in August of 2019 through a merger.
Priti, you want to comment about the plans for the pembrolizumab combination? And then we would start to explore a number of different combinations. About Neoleukin Therapeutics, Inc.Neoleukin is a biopharmaceutical company creating next generation immunotherapies for cancer, inflammation and autoimmunity usingde novoprotein design technology. And now Id like to recap our progress in 2021 and look ahead to milestones expected during 2022. The increase in G&A expenses in 2021 was primarily due to increases in personnel-related costs. So we actually see the opportunities is very broad and were starting off with monotherapy activity to see what the data look like. In addition, we showed that an NL-201 can turn cold tumors hot, expanding both the absolute number and clonal diversity of tumor-infiltrating T cells and increasing the amounts of interferon gamma and granzyme B produced in the tumor microenvironment. The agreement allows for the evaluation of safety and efficacy of NL-201 in combination with Mercks anti-PD-1 therapy, KEYTRUDA or pembrolizumab in our ongoing Phase 1 trial. February 25, 2020 08:00 ET Sure. FDICs Message to Crypto Investors: Digital Assets Arent Insured, Troubled Crypto Lender Babel Lost Big While Trading Client Funds, Ex-Voyager Executive Explores Competing Restructuring Plan for Crypto Lender, Former Chief Financial Officer, Neoleukin Therapeutics Inc. We hypothesize that this combination will enable a greater percentage of patients to benefit from immunotherapy and have the potential to move into earlier lines of therapy as a chemotherapy-free regimen. In addition, we plan to use information obtained from our solid tumor trial, as well as preclinical data to begin evaluation of NL-201 in hematologic malignancies. You know the patient number is really based around some expansion groups that we may want to look at in this setting, renal cell, melanoma, et cetera. Research and development expenses for the year were $39.2 million, compared to $24.3 million in 2020. Dukes will remain deputy chief financial officer through Aug. 1, 2020, and then will become senior managing director and CFO. Meineke franchisor Driven Brandsnamed Tiffany Masonas chief financial officer. During our three-year history, Neoleukin has built a state-of-the-art computational and protein engineering research organization. He received his Bachelor of Business Administration from the University of Notre Dame and his MBA from the University of Virginia Darden School of Business. Thank you. Thanks for the question, Charles. This guide discusses how to track the correct KPIs based on business needs, how those KPIs impact strategy and how to make sure theyve selected the right KPIs. Your line is open.
Well we would have to see how that goes. He has served as chief financial officer Jonathan Pruzans right hand since 2009. And now turning to our clinical program NL-201. Id like to begin with a few recent transitions at Neoleukin. NL-201 is a highly potent de novo protein that stimulates both the IL-2 and IL-15 receptors. Perhaps just one more, if you dont mind. So I would really think about the data were going to be presenting this year as preliminary and early and really informing what is the potential for NL-201. Great, thanks so much. Further information on potential risk factors that could affect Neoleukins business and its financial results are detailed under the heading Risk Factors in documents the Company files from time to time with theSecurities and Exchange Commission(SEC), and other reports as filed with theSEC. We also moved into our new headquarters in Seattle, with expanded lab and office space for our team. In May of last year, we treated our first patient in a Phase 1 clinical trial for NL-201, officially making the transition to become a clinical stage company. News Corp is a global, diversified media and information services company focused on creating and distributing authoritative and engaging content and other products and services. With that, now Im going to turn the call over to Sean Smith to discuss our year end 2021 financials. There will be some renal cell and melanoma in that mix but theres a wide variety of tumor types in dose escalation. I want to follow-up on the last question, maybe Ill ask it in a slightly different way and one I wonder whether you see as some PD markers being more predictive of potential clinical activity, whether thats overall CD8 expansion or CD8 to T-reg ratio. Its a very exciting time to join Neoleukin, as the company continues to advance its novel technology platform, and Im greatly looking forward to working with this dedicated, talented team, said Mr. Ho. Do you plan on developing NL-201 as a monotherapy in hematologic malignancies? Dukes most recently served as CFO of SunTrust Banks. Both Priti and Bill are great additions to our Neoleukin team and are making significant impacts, leading our clinical and research efforts. Good afternoon. Thomson Reuterssaid Mike Eastwood, senior vice president and head of corporate finance, will succeed Stephane Bello as chief financial officer on March 15. Throughout the past year, weve made strides in our research efforts as we explore the range of opportunities that Neoleukins de novo protein technology platform has to offer. Today, Id like to discuss our progress with the first-in-human Phase 1 clinical trial of NL-201. These statements are subject to numerous risks and uncertainties, including market conditions, that could cause actual results to differ materially from what Neoleukin expects. As a reminder, todays conference call is being recorded. But its not going to be a complete story, because were not going to have that long follow-up with large numbers of patients with specific indications. Last year, we presented preclinical data demonstrating that NL-201 has synergistic activity when combined with anti-PD-1 therapy, even in checkpoint refractory cancer models. Weve enjoyed connecting virtually with members of the investment and scientific community over the past year and look forward to meeting in person when the opportunity permits. So with theres a lot of interest obviously in this space. Source: FactSet. Insight and analysis of top stories from our award winning magazine "Bloomberg Businessweek". Your line is open. The increase in net loss, as mentioned, is primarily driven by increased clinical trial expense related to NL-201, increase in personnel costs and costs related to the build out of our headquarters in Seattle, Washington. Hi there. Most recently, Mr. Ho served as Senior Finance Director at DaVita, Inc. a publicly held, Fortune 500 company that is a leading provider of kidney care services in the U.S. And finally, we anticipate providing further information on progress with the research pipeline. Yeah. Bill is a skilled research leader who has guided research efforts on therapeutic candidates from discovery through clinical development utilizing novel platform technologies.
If you have an ad-blocker enabled you may be blocked from proceeding. Thanks, Sean. Previously, she served as managing director and head of West Coast Healthcare for Evercore Partners and managing director at Merrill Lynch. Im very pleased to announce that we also have a new Member of our Board of Directors, Rohan Palekar, who is currently the CEO of 89bio. Thanks for taking my question.
You may now disconnect. And similar to that, how should we also think about the potential patient follow-up that youll have, especially given that immuno-oncology approaches? We have been extremely fortunate to have Kams guidance these past months after the merger of the two companies. And weve seen that in our preclinical data. Before joining the drug maker, he held financial and operational leadership roles at American Express and Xerox. Sure.
I think you know at the end of 2022, there will be some preliminary efficacy for monotherapy that well take a look at.
We designed and NL-201 to be a potent activator of IL-2 and IL-15 responsive cells, without preferentially binding to cells expressing CD25. For more information, please visit the Neoleukin website:www.neoleukin.com. Anderson resigned from the company to pursue other opportunities. Good afternoon. So maybe not having to start at the very beginning of dose escalation, theres a lot of interests among investigators to start this combination in various tumor types. Ask an AI, I Got a Crash Course in Rodent Control atD.C.s RatAcademy. Neoleukin undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise. So just as a reminder, the first patient was dosed in May of last year. Well provide future updates regarding the status of Neo-5171 and potential development plans.
Sure. Neoleukin undertakes no obligation to update or revise any forward-looking statements. Im also kind of wondering, though, to what extent just given based on the inclusion criteria of your dose escalation, will you might you also have you know empirical data specifically within those patients heading into expansion cohorts? He became CFO in September 2019 to replace outgoing finance chief Muneera Carr. Wirth, who has been with the bank for 15 years, will stay on as a senior adviser through the end of the year.
By continuing to use our site, you agree to our cookie policy. Herzog joined Comerica in 1984 and was most recently executive vice president and treasurer. Your line is open. Sure. Source: FactSet, Indexes: Index quotes may be real-time or delayed as per exchange requirements; refer to time stamps for information on any delays. The increase was also due to facility-related costs associated with the build out of Neoleukins new laboratory and headquarters in Seattle, Washington.
We have good investigator engagements and are enrolling patients quickly. Please refer to the companys filings with the SEC which are available from the SEC or in the Neoleukin website for information concerning the risk factors that could affect the company. And we have assembled the talented team of more than 90 scientists, clinical developers and biotech professionals to advance our science and develop novel therapies to help patients with serious medical illnesses. Now obviously the selection of RP2D will be you know multifactorial base off of safety. Thanks, everybody for joining our call today. Cryptocurrencies: Cryptocurrency quotes are updated in real-time. Change value during the period between open outcry settle and the commencement of the next day's trading is calculated as the difference between the last trade and the prior day's settle. Eastwood has worked at Thomson Reuters for over 20 years, most recently as senior vice president and head of corporate finance since 2016.Eastwood was formerly chief operating officer of Thomson Reuters Latin America, CFO of the intellectual property and science business, and has also held several senior roles within the finance organization. The science underlying our technology has been published in the prestigious journals, Nature and Science. Thank you. Okay, great. First, we expect to report interim Phase 1 dose escalation data on NL-201 in the second half of the year. In this executive brief based on CFO's June 2022 webinar, you'll learn about the actionable insights CFOs can use to overcome workforce planning challenges amid economic volatility. I let Priti comment on that. Good afternoon, everyone and thanks for taking my questions. We appreciate the dedicated efforts of our talented team at Neoleukin and remain focused on our overriding goal to advance our de novo protein technology platform to benefit patients with serious diseases, including cancer, inflammation and autoimmune diseases. This business guide shares how CFOs from mCloud Technologies, Pact and Quatris Healthco are raising their finance teams profiles and shaping future business decisions. Priti previously served as Vice President, Head of Hematology Clinical Development at AstraZeneca and brings extensive experience in clinical development strategy and trial execution of investigational therapeutics with a specific expertise in oncology and hematologic malignancies. And as weve mentioned previously, due to the pandemic, particularly in 2021, there was some delays at some of the sites in getting it opened. Experimental results indicate that NL-201 causes expansion of cytotoxic memory CD8 T cells and a decrease in T-regulatory CD4 cells in the murine bone marrow. You know we expect dose escalation to start at a dose level, and these are learnings from what weve learned in monotherapy. And how is the current systemic trial informing whether thats an approach thats worth pursuing? By creating completely new molecules, we can optimize multiple parameters, including potency, affinity, stability, size and exactly which parts of the target receptors are engaged. This will be an important year for Neoleukin, as we learn about how our lead molecule performs in patients and continue to focus on extending the potential of our technology.
We ended 2021 with cash and cash equivalents of $142.5 million, compared to $192.6 million at the end of 2020. Lipper shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Meredithnamed Jason Frierottas the publishing companys new chief financial officer, effective March 9. Copyright FactSet Research Systems Inc. All rights reserved. Our next question comes from Joe Catanzaro with Piper Sandler. Cortenbach shares how he begins his day with meditation, the Robert Frost quote that inspires him, and his favorite leadership lesson. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. As a reminder, Neoleukin was founded at the end of 2018, went public in August of 2019 through a merger.
Priti, you want to comment about the plans for the pembrolizumab combination? And then we would start to explore a number of different combinations. About Neoleukin Therapeutics, Inc.Neoleukin is a biopharmaceutical company creating next generation immunotherapies for cancer, inflammation and autoimmunity usingde novoprotein design technology. And now Id like to recap our progress in 2021 and look ahead to milestones expected during 2022. The increase in G&A expenses in 2021 was primarily due to increases in personnel-related costs. So we actually see the opportunities is very broad and were starting off with monotherapy activity to see what the data look like. In addition, we showed that an NL-201 can turn cold tumors hot, expanding both the absolute number and clonal diversity of tumor-infiltrating T cells and increasing the amounts of interferon gamma and granzyme B produced in the tumor microenvironment. The agreement allows for the evaluation of safety and efficacy of NL-201 in combination with Mercks anti-PD-1 therapy, KEYTRUDA or pembrolizumab in our ongoing Phase 1 trial. February 25, 2020 08:00 ET Sure. FDICs Message to Crypto Investors: Digital Assets Arent Insured, Troubled Crypto Lender Babel Lost Big While Trading Client Funds, Ex-Voyager Executive Explores Competing Restructuring Plan for Crypto Lender, Former Chief Financial Officer, Neoleukin Therapeutics Inc. We hypothesize that this combination will enable a greater percentage of patients to benefit from immunotherapy and have the potential to move into earlier lines of therapy as a chemotherapy-free regimen. In addition, we plan to use information obtained from our solid tumor trial, as well as preclinical data to begin evaluation of NL-201 in hematologic malignancies. You know the patient number is really based around some expansion groups that we may want to look at in this setting, renal cell, melanoma, et cetera. Research and development expenses for the year were $39.2 million, compared to $24.3 million in 2020. Dukes will remain deputy chief financial officer through Aug. 1, 2020, and then will become senior managing director and CFO. Meineke franchisor Driven Brandsnamed Tiffany Masonas chief financial officer. During our three-year history, Neoleukin has built a state-of-the-art computational and protein engineering research organization. He received his Bachelor of Business Administration from the University of Notre Dame and his MBA from the University of Virginia Darden School of Business. Thank you. Thanks for the question, Charles. This guide discusses how to track the correct KPIs based on business needs, how those KPIs impact strategy and how to make sure theyve selected the right KPIs. Your line is open.
Well we would have to see how that goes. He has served as chief financial officer Jonathan Pruzans right hand since 2009. And now turning to our clinical program NL-201. Id like to begin with a few recent transitions at Neoleukin. NL-201 is a highly potent de novo protein that stimulates both the IL-2 and IL-15 receptors. Perhaps just one more, if you dont mind. So I would really think about the data were going to be presenting this year as preliminary and early and really informing what is the potential for NL-201. Great, thanks so much. Further information on potential risk factors that could affect Neoleukins business and its financial results are detailed under the heading Risk Factors in documents the Company files from time to time with theSecurities and Exchange Commission(SEC), and other reports as filed with theSEC. We also moved into our new headquarters in Seattle, with expanded lab and office space for our team. In May of last year, we treated our first patient in a Phase 1 clinical trial for NL-201, officially making the transition to become a clinical stage company. News Corp is a global, diversified media and information services company focused on creating and distributing authoritative and engaging content and other products and services. With that, now Im going to turn the call over to Sean Smith to discuss our year end 2021 financials. There will be some renal cell and melanoma in that mix but theres a wide variety of tumor types in dose escalation. I want to follow-up on the last question, maybe Ill ask it in a slightly different way and one I wonder whether you see as some PD markers being more predictive of potential clinical activity, whether thats overall CD8 expansion or CD8 to T-reg ratio. Its a very exciting time to join Neoleukin, as the company continues to advance its novel technology platform, and Im greatly looking forward to working with this dedicated, talented team, said Mr. Ho. Do you plan on developing NL-201 as a monotherapy in hematologic malignancies? Dukes most recently served as CFO of SunTrust Banks. Both Priti and Bill are great additions to our Neoleukin team and are making significant impacts, leading our clinical and research efforts. Good afternoon. Thomson Reuterssaid Mike Eastwood, senior vice president and head of corporate finance, will succeed Stephane Bello as chief financial officer on March 15. Throughout the past year, weve made strides in our research efforts as we explore the range of opportunities that Neoleukins de novo protein technology platform has to offer. Today, Id like to discuss our progress with the first-in-human Phase 1 clinical trial of NL-201. These statements are subject to numerous risks and uncertainties, including market conditions, that could cause actual results to differ materially from what Neoleukin expects. As a reminder, todays conference call is being recorded. But its not going to be a complete story, because were not going to have that long follow-up with large numbers of patients with specific indications. Last year, we presented preclinical data demonstrating that NL-201 has synergistic activity when combined with anti-PD-1 therapy, even in checkpoint refractory cancer models. Weve enjoyed connecting virtually with members of the investment and scientific community over the past year and look forward to meeting in person when the opportunity permits. So with theres a lot of interest obviously in this space. Source: FactSet. Insight and analysis of top stories from our award winning magazine "Bloomberg Businessweek". Your line is open. The increase in net loss, as mentioned, is primarily driven by increased clinical trial expense related to NL-201, increase in personnel costs and costs related to the build out of our headquarters in Seattle, Washington. Hi there. Most recently, Mr. Ho served as Senior Finance Director at DaVita, Inc. a publicly held, Fortune 500 company that is a leading provider of kidney care services in the U.S. And finally, we anticipate providing further information on progress with the research pipeline. Yeah. Bill is a skilled research leader who has guided research efforts on therapeutic candidates from discovery through clinical development utilizing novel platform technologies.
If you have an ad-blocker enabled you may be blocked from proceeding. Thanks, Sean. Previously, she served as managing director and head of West Coast Healthcare for Evercore Partners and managing director at Merrill Lynch. Im very pleased to announce that we also have a new Member of our Board of Directors, Rohan Palekar, who is currently the CEO of 89bio. Thanks for taking my question.